Takeda's TYK2 inhibitor shows promising phase 2 results in psoriasis

NEW ORLEANS — Phase 2b clinical trial results of Takeda Pharmaceuticals’ novel tyrosine kinase 2 inhibitor found significantly greater skin clearance in study patients compared with placebo, according to a presentation here.
In the phase 2b, randomized, double-blind, placebo-controlled study, April W. Armstrong, MD, MPH, FAAD, professor of dermatology and associate dean for clinical

Related Keywords

United States ,American ,Galderma Incyte ,Kristen Dowd ,Byrebeccal Forand ,Ventyx Biosciences ,Sanofi Genzyme ,Aprilw Armstrong ,Eli Lilly ,Sun Pharmaceuticals ,American Academy Of Dermatology Annual Meeting ,Beiersdorf ,Boehringer Ingelheim ,Novartis ,Pfizer ,Bristol Myers Squibb ,American Academy ,Dermatology Annual Meeting ,Modernizing Medicine ,Nimbus Therapeutics ,Ortho Dermatologics ,Takeda Pharmaceutical ,Keck School ,Southern California ,Dermatology Annual ,